• Share
  • Email
  • Print

C. Rachal Winger, Ph.D.

Fax +1.206.623.7022
Fax +1.949.253.0902

Rachal Winger, Ph.D. focuses her practice on intellectual property law with an emphasis in life sciences patent-related matters. Rachal counsels her clients in the creation and commercialization of intellectual property and in the assessment of others parties’ intellectual property in corporate transactions and competitive analyses. These endeavors include domestic and international patent prosecution and portfolio management, due diligence, patentability and freedom-to-operate assessments, and litigation evaluation and support.

Rachal's clients include start-ups, emerging growth companies financed by grants, private equity and venture capital investors, universities, and multi-national companies in the pharmaceutical and health care fields. She has expertise in a wide breadth of technologies including:

  • The screening and development of anti-viral compounds, anti-biofilm compounds and anti-inflammatory compounds;
  • Diagnostics including genetic and biomarker assays for chronic and/or progressive conditions;
  • Pain management;
  • Therapeutics for cancers, neurodegenerative diseases, mental disorders, metabolic disorders, bone disorders and ocular diseases;
  • Regenerative stem cell technologies;
  • Targeted drug delivery using nanotechnology;
  • Medical and research-related devices; and
  • Other life-science related innovations including cosmetics, dietary supplements and physical therapy and training devices.

Rachal has served as an instructor for the University of Washington's Certificate in Intellectual Property Management Program and as an adjunct instructor of intellectual property at the University of Washington. She is a frequent speaker domestically and internationally on intellectual property development strategies within the evolving legal landscape to investment groups, patent practitioners and business leaders.

Professional Background

Before attending law school, Rachal earned a Ph.D. in Behavioral Neuroscience supported in part by an Individual National Research Service Award. Her dissertation examined the effects of immune activation on brain function and included developing and treating an animal model of AIDS-related dementia.

Speaking Engagements

    • Patent Law: Reformed but Unrepented. Washington Biomedical & Biotechnology Association Annual Innovation Northwest Conference, Seattle Washington. Winger, C.R., Panel Moderator (2012).
    • Enterprise Architecture: Tips for Building a Fundable Company, Alliance of Angels & Washington Technology Industry Association, Seattle, Washington. Winger, C.R., Panelist. (2012).
    • Framing Patent Applications for Current U.S. Standards – A 35 U.S.C. § 101 Update. CII Life Science Conclave, New Delhi, India. Winger, C.R. (2011).
    • Patent Law Update. Alliance of Angels, Seattle, Washington. Winger, C.R. (2010).
    • United States Intellectual Property Law. Seoul, Korea. Winger, C.R. (2008).
    • The Law of Obviousness. Invited Guest Lecturer, Seattle University School of Law. Winger, C.R. (2004).
    • Immune System Effects on Motivational Systems.  Invited Guest Lecturer, San Francisco State University. Pugh, C. R. (2001). 
    • Affective & Behavioral Effects of Immune Activation.  Invited Guest Lecturer, University of Colorado, Boulder. Pugh, C. R. (1999). 
    • Selective LPS & IL-1? effects on fear conditioning: A role for cytokines in learning and memory processes. Annual Psychoneuroimmunology Research Society Meeting. Pugh, C. R., Nguyen, K. T., Fleshner, M., Watkins. L. R., Maier, S. F., & Rudy, J. W. (1998).
    • LPS administered after fear conditioning disrupts contextual but not auditory-cue fear conditioning: A possible role for brain cytokines in memory consolidation. Annual Psychoneuroimmunology Research Society Meeting. Pugh, C. R., Fleshner, M., Watkins, L. R., Maier, S. F., & Rudy, J. W. (1997).

    Selected Publications

    • "Did University Patents Become the World's Most Valuable Patents Following Enactment of the America Invents Act?," Intellectual Property Today, Barrett, R.M., Birdsall, M. & Winger, C.R. (2012).
    • "Case Note:  Bernier v. Merrill Air Engineers,” Berkeley Technology Law Journal Annual Review of Law & Technology, 17(1), 231-250. Pugh, C. R. (2002).
    • “Further characterization of high mobility group box 1 (HMGB1) as a proinflammatory cytokine:  Central nervous system effects,”  Cytokine, 24, 254-265. O’Connor, K. A., Hansen, M. K., Pugh, C. R., Deak, M. M., Biedenkapp, J. C., Milligan, E. D., Johnson, J. D., Wang, H., Maier, S. F., Tracey, K. J., Watkins, L. R. (2003). 
    • "The immune system and memory consolidation:  A role for the cytokine interleukin-1 beta,”  Neuroscience and Biobehavioral Reviews, 25, 29-41. Pugh, C. R., Fleshner, M., Watkins, L. R., Maier, S. F., & Rudy, J. W. (2001). 
    • "Human immunodeficiency virus-1 coat protein gp120 impairs contextual fear conditioning: A potential role in AIDS related learning and memory impairments,” Brain Research, 861, 8-15. Pugh, C. R., Johnson, J. D., Martin, D.,  Rudy, J. W., Maier, S. F., & Watkins, L. R. (2000).
    • "Role of interleukin-1 beta in impairment of contextual fear conditioning caused by social isolation,” Behavioral Brain Research, 106, 109-118. Pugh, C. R., Nguyen, K. T., Gonyea, J. L., Fleshner, M., Watkins, L. R., Maier, S. F., & Rudy, J. W. (1999).
    • "Selective effects of peripheral lipopolysaccharide administration on contextual and auditory-cue fear conditioning,” Brain, Behavior, and Immunity, 12, 212-229. Pugh, C. R., Kumagawa, K., Fleshner, M., Watkins, L. R., Maier, S. F., & Rudy, J. W. (1998).
    • “DHEAS selectively impairs contextual fear conditioning: Support for the anti-glucocorticoid hypothesis,” Behavioral Neuroscience, 111(3), 512-517. Fleshner, M., Pugh, C. R., Tremblay, D., & Rudy, J. W. (1997).
    • "A selective role for corticosterone in contextual fear conditioning,” Behavioral Neuroscience, 111(3), 503-511. Pugh, C. R., Tremblay, D., Fleshner, M., & Rudy, J. W. (1997).